Profil bibliographique

Ronan Swords

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

302Publications signalées

9856Citations signalées

2Affiliations récentes

Institutions déclarées

Oregon Health & Science University OHSU Knight Cancer Institute

Domaines associés

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchMyeloproliferative Neoplasms: Diagnosis and Treatment

Publications récentes

Accès ouvert 2026 articleOpenAlex

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia (AML) ≥ Age 60 years.

Joshua F. Zeidner, Matthew C. Foster, Ying Huang, Eric D. Eisenmann et autres

0 citationsUNC Libraries

Accès ouvert 2026 articleOpenAlex

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Michael J. Hochman, Amy S. Ruppert, Ying Huang, Alice Mims et autres

0 citationsHaematologica

Accès ouvert 2026 articleOpenAlex

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia

Uma Borate, Cristina E. Tognon, Yazan F. Madanat, Shikha Misra et autres

0 citationsBlood Neoplasia

2026 articleOpenAlex

Allogeneic Transplant Outcomes in Adults Aged ≥75 Receiving Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide

Howard Y. Chang, Staci Williamson, Daniel Chandra, Andy Chen et autres

0 citationsTransplantation and Cellular Therapy

2026 articleOpenAlex

Allogeneic Transplant Outcomes in Patients Aged ≥70 Vs <70 with Fludarabine/Melphalan Conditioning and Post-Transplant Cyclophosphamide

Howard Y. Chang, Staci Williamson, Daniel Chandra, Andy Chen et autres

0 citationsTransplantation and Cellular Therapy

2026 articleOpenAlex

Comparative Outcomes of 80 Mg/kg2 Vs 100 Mg/Kg 2 Post-Transplant Cyclophosphamide Following FluMel100 Conditioning in Allogeneic Hematopoietic Cell Transplantation

Howard Y. Chang, Staci Williamson, Daniel Chandra, Andy Chen et autres

0 citationsTransplantation and Cellular Therapy

2025 conference-abstractOpenAlex

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose, Elizabeth O. Hexner et autres

1 citationBlood

Accès ouvert 2025 conference-abstractOpenAlex

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Howard H. Chang, Staci Williamson, Daniel Chandra, Andy Chen et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Uma Borate, Shivani Handa, Kaitlyn Dvorak‐Kornaus, Ronan Swords et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Kelli Goslee, Chelsea Bowman, Victoria Cooper, Gabrielle Meyers et autres

0 citationsBlood

2025 conference-abstractOpenAlex

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Howard H. Chang, Staci Williamson, Daniel Chandra, Andy Chen et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Fieke W. Hoff, Alexander Li, Ying Huang, Rina Li Welkie et autres

1 citationBlood

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.